Article

Immune-related adverse-event signals of durvalumab: cross-database pharmacovigilance analysis of WHO-VigiAccess and FAERS with comparative assessment versus atezolizumab

2026-04-21

Abstract excerpt

<title>Abstract</title> <p>Background: Durvalumab has become a key programmed death-ligand 1 (PDL1) inhibitor in modern oncology, particularly in thoracic malignancies. As its clinical use expands, immune-related adverse events (irAEs) have emerged as a major safety concern. However, comprehensive real-world characterization of durvalumab-associated irAEs and direct comparison with other PD-L1 inhibitors remain l...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 242a7034-3793-5b72-9af3-100c15f67d93
DOI: 10.21203/rs.3.rs-9154831/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immune-related adverse-event signals of durvalumab: cross-database pharmacovigilance analysis of WHO-VigiAccess and FAERS with comparative assessment versus atezolizumabDOI 10.21203/rs.3.rs-9154831/v1Read

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read

Adverse event profile differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: a real-world, pharmacovigilance studySemantic proximity Read

Reported Drug Spectrum and Disproportionality Signals for Malignant Neoplasm Progression in FAERS: A Real-World Pharmacovigilance StudySemantic proximity Read

Cross-Database Analysis of Fruquintinib-Associated adverse events: Insights from FAERS and VigiAccess databasesSemantic proximity Read

Real-world safety profile of Enfortumab Vedotin: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS)Semantic proximity Read

Adverse Event Profiles of CDK4/6 inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseSemantic proximity Read

A Real-World Disproportionality Analysis of Two Typical First-Generation TRK Inhibitors: Findings from the FDA Adverse Event Reporting System DatabaseSemantic proximity Read

Baseline risk factors associated with immune related adverse events and atezolizumabSemantic proximity Read

Safety Analysis of Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Real-World Study Based on the FAERS DatabaseSemantic proximity Read

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for OsimertinibSemantic proximity Read

Hepatic Failure Associated with Immune Checkpoint Inhibitors: A Real-world Study from the Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseSemantic proximity Read

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read